Bulletin
Investor Alert

Laboratory Corp. of America Holdings

NYS: LH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Apr 16, 2021, 7:55 p.m.

LH
/zigman2/quotes/203174601/composite

$

264.99

Change

+2.79 +1.06%

Volume

Volume 16,570

Quotes are delayed by 20 min

/zigman2/quotes/203174601/composite

Previous close

$ 259.41

$ 262.20

Change

+2.79 +1.08%

Day low

Day high

$256.75

$263.08

Open

52 week low

52 week high

$141.32

$263.08

Open

Company Description

Laboratory Corp. of America Holdings operates as a life sciences y, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead op...

Laboratory Corp. of America Holdings operates as a life sciences y, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1995 and is headquartered in Burlington, NC.

Valuation

P/E Current

16.34

P/E Ratio (with extraordinary items)

16.39

P/E Ratio (without extraordinary items)

12.82

Price to Sales Ratio

1.43

Price to Book Ratio

2.12

Price to Cash Flow Ratio

9.34

Enterprise Value to EBITDA

6.47

Enterprise Value to Sales

1.82

Total Debt to Enterprise Value

0.27

Efficiency

Revenue/Employee

193,073.00

Income Per Employee

21,493.00

Receivables Turnover

5.54

Total Asset Turnover

0.73

Liquidity

Current Ratio

1.66

Quick Ratio

1.53

Cash Ratio

0.43

Profitability

Gross Margin

33.46

Operating Margin

21.24

Pretax Margin

15.88

Net Margin

11.13

Return on Assets

8.16

Return on Equity

18.39

Return on Total Capital

19.26

Return on Invested Capital

10.52

Capital Structure

Total Debt to Total Equity

72.19

Total Debt to Total Capital

41.92

Total Debt to Total Assets

33.66

Long-Term Debt to Equity

66.04

Long-Term Debt to Total Capital

38.35

Officers and Executives

Name Age Officer Since Title
Mr. Adam H. Schechter 55 2013 Lead Independent Director
Mr. Glenn Andrew Eisenberg 59 2014 Chief Financial Officer & Executive Vice President
Mr. Stephen M. Anderson - - Chief Scientific Officer-Covance & Senior VP
Mr. Lance V. Berberian 57 2014 Chief Information & Technology Officer & EVP
Dr. Brian J. Caveney 45 2017 Chief Medical Officer, EVP & President-Diagnostics

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/03/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
452   Derivative/Non-derivative trans. at $252.67 per share. 114,206
04/03/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
1,010   Derivative/Non-derivative trans. at $0 per share. 0
03/30/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
812   Disposition at $251.88 per share. 204,526
03/30/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
667   Disposition at $251.88 per share. 168,003
03/27/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
3,595   Derivative/Non-derivative trans. at $251.58 per share. 904,430
03/27/2021 Lance V. Berberian
EVP, CIO & CTO
1,079   Derivative/Non-derivative trans. at $251.58 per share. 271,454
03/27/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
790   Derivative/Non-derivative trans. at $251.58 per share. 198,748
03/27/2021 Brian J. Caveney
EVP, President of Diagnostics
1,079   Derivative/Non-derivative trans. at $251.58 per share. 271,454
03/27/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
687   Derivative/Non-derivative trans. at $251.58 per share. 172,835
03/27/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
1,079   Derivative/Non-derivative trans. at $251.58 per share. 271,454
03/27/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
8,042   Award at $0 per share. 0
03/27/2021 Lance V. Berberian
EVP, CIO & CTO
2,413   Award at $0 per share. 0
03/27/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
2,104   Award at $0 per share. 0
03/27/2021 Brian J. Caveney
EVP, President of Diagnostics
2,413   Award at $0 per share. 0
03/27/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
2,310   Award at $0 per share. 0
03/27/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
2,413   Award at $0 per share. 0
02/18/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
633   Derivative/Non-derivative trans. at $182.51 per share. 115,528
02/18/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
1,533   Derivative/Non-derivative trans. at $146.59 per share. 224,722
02/18/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
2,317   Disposition at $241.51 per share. 559,578
02/16/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
100   Disposition at $236.05 per share. 23,605
02/16/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
5   Disposition at $235.89 per share. 1,179
02/16/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
103   Disposition at $237.06 per share. 24,417
02/16/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
85   Disposition at $237.06 per share. 20,150
02/16/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
103   Disposition at $237.06 per share. 24,417
02/12/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
280   Derivative/Non-derivative trans. at $238.26 per share. 66,712
02/12/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
232   Derivative/Non-derivative trans. at $238.26 per share. 55,276
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
105   Derivative/Non-derivative trans. at $238.26 per share. 25,017
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
699   Derivative/Non-derivative trans. at $238.26 per share. 166,543
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
69   Derivative/Non-derivative trans. at $238.26 per share. 16,439
02/12/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
93   Derivative/Non-derivative trans. at $238.26 per share. 22,158
02/12/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
87   Derivative/Non-derivative trans. at $238.26 per share. 20,728
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
699   Derivative/Non-derivative trans. at $238.26 per share. 166,543
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
85   Derivative/Non-derivative trans. at $238.26 per share. 20,252
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
70   Derivative/Non-derivative trans. at $238.26 per share. 16,678
02/12/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
78   Derivative/Non-derivative trans. at $238.26 per share. 18,584
02/12/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
80   Derivative/Non-derivative trans. at $238.26 per share. 19,060
02/12/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
78   Derivative/Non-derivative trans. at $238.26 per share. 18,584
02/12/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
64   Derivative/Non-derivative trans. at $238.26 per share. 15,248
02/12/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
201   Derivative/Non-derivative trans. at $238.26 per share. 47,890
02/12/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
62   Derivative/Non-derivative trans. at $238.26 per share. 14,772
02/12/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
940   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
780   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
353   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
2,353   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Lance V. Berberian
EVP, CIO & CTO
234   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
317   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
264   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
2,353   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
283   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Brian J. Caveney
EVP, President of Diagnostics
234   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
283   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
290   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
283   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
234   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
680   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
187   Derivative/Non-derivative trans. at $0 per share. 0
02/05/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
109   Disposition at $225.85 per share. 24,617
02/05/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
203   Disposition at $225.85 per share. 45,847
02/04/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
306   Derivative/Non-derivative trans. at $223.78 per share. 68,476
02/04/2021 Jean-Luc Bélingard
Director
99   Derivative/Non-derivative trans. at $223.78 per share. 22,154
02/04/2021 Lance V. Berberian
EVP, CIO & CTO
131   Derivative/Non-derivative trans. at $223.78 per share. 29,315
02/04/2021 Adam H. Schechter
President & CEO; Director
1,028   Derivative/Non-derivative trans. at $223.78 per share. 230,045
02/04/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
187   Derivative/Non-derivative trans. at $223.78 per share. 41,846
02/04/2021 Brian J. Caveney
EVP, President of Diagnostics
190   Derivative/Non-derivative trans. at $223.78 per share. 42,518
02/04/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
83   Derivative/Non-derivative trans. at $223.78 per share. 18,573
02/04/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
154   Derivative/Non-derivative trans. at $223.78 per share. 34,462
02/04/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
53   Derivative/Non-derivative trans. at $223.78 per share. 11,860
02/04/2021 Judith C. Seltz
EVP, CHRO
96   Derivative/Non-derivative trans. at $223.78 per share. 21,482
02/04/2021 Amy B. Summy
EVP, Chief Marketing Officer
94   Derivative/Non-derivative trans. at $223.78 per share. 21,035
02/04/2021 Glenn Andrew Eisenberg
Chief Financial Officer, EVP
970   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Kerrii B. Anderson
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Jean-Luc Bélingard
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Lance V. Berberian
EVP, CIO & CTO
373   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Adam H. Schechter
President & CEO; Director
3,506   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Peter M. Neupert
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Paul R. Kirchgraber
CEO, Covance Drug Development
560   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Garheng Kong
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Brian J. Caveney
EVP, President of Diagnostics
560   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 D. Gary Gilliland
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Robert Sanders Williams
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Richelle P. Parham
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Sandra Danett van der Vaart
EVP, Chief Legal Officer
300   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Mark S. Schroeder
EVP, President-Diagnostics Lab
560   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Jeffrey Allan Davis
Director
986   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Peter J. Wilkinson
SVP, Chief Accounting Officer
150   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Judith C. Seltz
EVP, CHRO
280   Derivative/Non-derivative trans. at $0 per share. 0
02/04/2021 Amy B. Summy
EVP, Chief Marketing Officer
266   Derivative/Non-derivative trans. at $0 per share. 0
01/26/2021 Robert Sanders Williams
Director
1,300   Derivative/Non-derivative trans. at $98.49 per share. 128,037
12/03/2020 Kerrii B. Anderson
Director
746   Gift at $0 per share. 0
/news/latest/company/us/lh

MarketWatch News on LH

  1. Laboratory Corp. of America Holdings stock falls Tuesday, underperforms market

    5:06 p.m. April 13, 2021

    - MarketWatch Automation

  2. Laboratory Corp. of America Holdings stock rises Monday, outperforms market

    5:05 p.m. April 12, 2021

    - MarketWatch Automation

  3. Loading more headlines...
/news/nonmarketwatch/company/us/lh

Other News on LH

  1. Syneos Health gains following Thermo Fisher $17B deal for PPD

    10:34 a.m. April 15, 2021

    - Seeking Alpha

  2. Thermo Fisher Nears Deal to Buy PPD for More Than $15 Billion

    3:59 p.m. April 14, 2021

    - Jonathan D. Rockoff

  3. PPD gains after report Thermo Fisher nearing $15B deal

    3:52 p.m. April 14, 2021

    - Seeking Alpha

  4. 7 Tech Stocks Becoming Healthcare Stocks

    11:34 a.m. April 1, 2021

    - InvestorPlace.com

  5. LabCorp (LH) Moves 4.9% Higher: Will This Strength Last?

    6:35 a.m. March 25, 2021

    - Zacks.com

  6. Labcorp hires Goldman Sachs for company business review

    5:41 p.m. March 23, 2021

    - Seeking Alpha

  7. Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

    10:06 a.m. March 19, 2021

    - Zacks.com

  8. Loading more headlines...

At a Glance

Laboratory Corp. of America Holdings

358 South Main Street

Burlington, North Carolina 27215-5837

Phone

1 3362291127

Industry

Healthcare Provision

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$13.98B

Net Income

$1.56B

2020 Sales Growth

21.0%

Employees

72,400

/news/pressrelease/company/us/lh

Press Releases on LH

  1. Labcorp to Webcast Its Annual Meeting of Shareholders

    7:01 a.m. April 16, 2021

    - BusinessWire - BZX

  2. Clinical Laboratory Tests Market Report 2021-2031

    10:44 a.m. April 15, 2021

    - GlobeNewswire

  3. Precision Medicine Market Report 2020-2030

    7:32 a.m. April 13, 2021

    - GlobeNewswire

  4. Loading more headlines...
Link to MarketWatch's Slice.